MedTrace Logo

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-03-12

No results posted yet for this study

Summary

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Conditions

  • Upper Respiratory Disease
  • Influenza
  • Viral Upper Respiratory Infection

Interventions

DIETARY_SUPPLEMENT

Immune Defense Protein 50mg Dose

IDP dose of 50mg

DIETARY_SUPPLEMENT

IDP 200mg Dose

IDP dose of 200mg

DIETARY_SUPPLEMENT

Matching Placebo

Matching Placebo

Sponsors & Collaborators

  • People Science, Inc.

    collaborator INDUSTRY

  • Quantec Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2026-05-19
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07431840 on ClinicalTrials.gov